Apply for funding to discover more about the potential market of your bioscience-based idea, increase market awareness and gain deeper understanding of potential technology applications.
BBSRC ICURe Discover is open to bioscience researchers (including PhD students, technicians, postdoctoral research associates, fellowship and group leader positions) in all UK universities, BBSRC-funded institutes and approved public sector research enterprises.
Apply for funding to spend time in a different research or user environment to build new skills and collaborations within health technologies. Novel engineering and physical sciences research must comprise a proportion of the placement.
You must be based at a UK research organisation eligible for EPSRC funding.
Successful applicants to the Future Leaders Fellowship (FLF) can apply to extend their four-year fellowship by up to a further three years. Renewals will continue to support the development of a leading-edge fellow and further their work to undertake adventurous, ambitious programmes that tackle difficult and novel challenges.
Apply for funding to develop open educational resources for the training of artificial intelligence (AI) developers, users, managers, the public and other stakeholders.
You and your organisation must be eligible for UK Research and Innovation (UKRI) funding.
Apply for funding to develop a NetworkPlus focused on the use and development of novel tools and technologies to enable people with dementia to live independently.
Networks should be multidisciplinary and embed people with lived experiences of dementia.
You must be based at a UK research organisation eligible for EPSRC funding.
UK registered micro, small and medium enterprises in the creative sector can apply for funding of between £10,000 and £30,000 for innovation projects to grow their business.
Apply for funding to run a High Throughput Screen (HTS) using AstraZeneca’s compound library and screening robots.
Two funding opportunities per year with changing themes. This funding opportunity will have a focus on new targets related to Fibrosis or Extracellular Matrix.